Comparative Pharmacology
Head-to-head clinical analysis: METRA versus METROGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRA versus METROGEL.
METRA vs METROGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
Adults: 20 mg orally once daily.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
None Documented
None Documented
Terminal elimination half-life: 3-7 hours (mean 4.5 hours). Increased to 8-15 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderatePhenmetrazine + Atomoxetine
"Phenmetrazine may increase the hypertensive activities of Atomoxetine."
Clinical Note
moderatePhenmetrazine + Iobenguane
"The therapeutic efficacy of Iobenguane can be decreased when used in combination with Phenmetrazine."
Clinical Note
moderatePhenmetrazine + Acebutolol
"The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Acebutolol."
Clinical Note
moderatePhenmetrazine + Isoxsuprine
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
Primarily renal: 70-80% unchanged drug via glomerular filtration and active tubular secretion; 15-20% biliary/fecal as metabolites.
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)
"The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Isoxsuprine."